Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company

Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency

Fineline Cube Aug 28, 2024

Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952),...

Company Drug

JW Therapeutics’ CAR-T Therapy Carteyva Secures NMPA Approval for Mantle Cell Lymphoma Indication

Fineline Cube Aug 28, 2024

JW Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Drug

Shanghai-Based ANEXT Commences Clinical Trials for Exosome Product ANEXT FIT CELL in Respiratory Conditions

Fineline Cube Aug 28, 2024

ANEXT, a Shanghai-based exosome specialist, has launched two clinical studies for their product ANEXT FIT...

Company

Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report

Fineline Cube Aug 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...

Company Deals

Shanghai BDgene Partners with SPH RD to Develop Hemophilia Treatments Using BDlendi Insulator Technology

Fineline Cube Aug 28, 2024

Shanghai BDgene Technology Co., Ltd, a leading gene therapy specialist based in China, has entered...

Company Drug

Legend Biotech’s Carvykti Receives NMPA Approval for Relapsed/Refractory Multiple Myeloma After Multi-Center Phase II Study

Fineline Cube Aug 28, 2024

Legend Biotech Corporation (NASDAQ: LEGN) has secured a significant milestone with the announcement of marketing...

Company Drug

Jiangsu Hengrui’s Vunakizumab Receives NMPA Approval as First Homegrown Autoimmune IL-17A Drug

Fineline Cube Aug 28, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...

Company

Luye Pharma’s Subsidiary Boan Bio Reports 2024H1 Revenue Growth and First Full Year of Profitability

Fineline Cube Aug 28, 2024

Luye Pharma Group, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2186), has announced...

Company Drug

Hinova Pharmaceuticals’ HP515 Receives NMPA Approval for NASH Clinical Study

Fineline Cube Aug 28, 2024

Hinova Pharmaceuticals Inc., a biotech firm headquartered in Chengdu and listed on the Shanghai Stock...

Company

Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition

Fineline Cube Aug 28, 2024

Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE:...

Company Drug

Bio-Thera Solutions’ BAT8006 Receives NMPA Approval for Clinical Trial in Recurrent Ovarian Cancer Maintenance Therapy

Fineline Cube Aug 28, 2024

Bio-Thera Solutions, a biopharmaceutical company based in Guangzhou and listed on the Shanghai Stock Exchange...

Company Drug

Chongqing Genrix Biopharmaceutical Receives NMPA Approval for Xeligekimab, First Domestic Anti-IL-17 Antibody

Fineline Cube Aug 27, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has received marketing approval from China’s...

Legal / IP

Takeda’s Entyvio Receives Historic Patent Term Adjustment in China, a First for the Country

Fineline Cube Aug 27, 2024

On August 16, a significant milestone was reached as the China National Intellectual Property Administration...

Policy / Regulatory

NHSA Updates NRDL Review, Adds Three Domestic Western Medicines

Fineline Cube Aug 27, 2024

The National Healthcare Security Administration (NHSA) has issued a notification regarding the review and correction...

Company Drug

Regeneron Secures EU Approval for Ordspono, Its First Bispecific Antibody

Fineline Cube Aug 27, 2024

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has secured its first global market approval for Ordspono (odronextamab)...

Company

BeiGene Positions for Global Growth with Strong Half-Year Results and R&D Investment

Fineline Cube Aug 27, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) reported robust second-quarter 2024 results, highlighting significant corporate...

Legal / IP

Peking Union Medical College Innovates with Angle Positioning Device Patent Sale

Fineline Cube Aug 27, 2024

Peking Union Medical College Hospital (PUMCH) has announced its intention to transfer the patent for...

Company Deals

China’s WORK Medical Technology Targets U.S. Market with Upcoming IPO

Fineline Cube Aug 27, 2024

China-based WORK Medical Technology Group Ltd has priced its initial public offering (IPO) at USD...

Company

UCB Agrees to USD 680 Million Divestment of China Neurology and Allergy Business to CBC Group and Mubadala

Fineline Cube Aug 27, 2024

UCB, a Belgium-based biopharmaceutical company listed on the Brussels Stock Exchange (FRA: UNC), has announced...

Company Deals

Shenzhen Salubris Pharmaceuticals Inks Licensing Deal for YolTech Therapeutics’ YOLT-101 Gene Editing Therapy

Fineline Cube Aug 27, 2024

Shenzhen Salubris Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange...

Posts pagination

1 … 302 303 304 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.